Back to Search
Start Over
Patients with Obstructive Sleep Apnea Have Cardiac Repolarization Disturbances when Travelling to Altitude: Randomized, Placebo-Controlled Trial of Acetazolamide.
- Source :
-
Sleep [Sleep] 2016 Sep 01; Vol. 39 (9), pp. 1631-7. Date of Electronic Publication: 2016 Sep 01. - Publication Year :
- 2016
-
Abstract
- Study Objectives: Obstructive sleep apnea (OSA) promotes myocardial electrical instability and may predispose to nocturnal sudden cardiac death. We evaluated whether hypobaric hypoxia during altitude travel further impairs cardiac repolarization in patients with OSA, and whether this is prevented by acetazolamide, a drug known to improve oxygenation and central sleep apnea at altitude.<br />Methods: Thirty-nine OSA patients living < 600 m, discontinued continuous positive airway pressure therapy during studies at 490 m and during two sojourns of 3 days at altitude (2 days at 1860 m, 1 day at 2590 m). During one altitude sojourn, patients took acetazolamide, during the other placebo, or vice versa, according to a randomized, double-blind crossover design. Twelve-lead electrocardiography and pulse oximetry (SpO2) were recorded during nocturnal polysomnography. Heart rate corrected mean QT intervals during the entire night (meanQTc) and during 1 min of the night with the longest meanQTc (maxQTc) were determined.<br />Results: At 490 m the median nocturnal SpO2 was 93%, medians of meanQTc and maxQTc were 420 ms and 478 ms. At 2590 m, on placebo, SpO2 was lower (85%), and meanQTc and maxQTc were prolonged to 430 ms and 510 ms (P < 0.02 vs. 490 m, all corresponding comparisons). At 2590 m on acetazolamide, median SpO2 was increased to 88% (P < 0.05 vs. placebo), meanQTc was reduced to 427 ms (P < 0.05 vs. placebo), whereas maxQTc remained increased at 502 ms (P = ns vs. placebo).<br />Conclusions: At 2590 m OSA patients experienced cardiac repolarization disturbances in association with hypoxemia. Prolongation of meanQTc at altitude was prevented and hypoxemia was improved by acetazolamide, whereas maxQTc remained increased suggesting imperfect protection from repolarization disturbances.<br />Clinical Trial Registration: ClinicalTrials.gov ID: NTC-00714740. URL: www.clinicaltrials.gov.<br /> (© 2016 Associated Professional Sleep Societies, LLC.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Arrhythmias, Cardiac etiology
Cross-Over Studies
Double-Blind Method
Female
Humans
Hypoxia etiology
Male
Middle Aged
Oximetry
Polysomnography
Sleep Apnea, Obstructive complications
Acetazolamide therapeutic use
Altitude
Arrhythmias, Cardiac prevention & control
Carbonic Anhydrase Inhibitors therapeutic use
Hypoxia physiopathology
Sleep Apnea, Obstructive physiopathology
Subjects
Details
- Language :
- English
- ISSN :
- 1550-9109
- Volume :
- 39
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Sleep
- Publication Type :
- Academic Journal
- Accession number :
- 27306264
- Full Text :
- https://doi.org/10.5665/sleep.6080